About the Company

Aimmune Therapeutics (NasdaqGS: AIMT) is a clinical stage biopharmaceutical company developing allergy desensitization treatments for patients with peanut and other food allergies. No therapies are available to address the growing prevalence of severe peanut allergies, leaving these patients at risk of life-threatening anaphylaxis upon accidental exposure to peanuts. Aimmune’s lead product candidate is AR101, a proprietary peanut formulation based on the Company’s characterized oral desensitization immunotherapy (CODIT) platform. AR101, which has Breakthrough Therapy designation from the FDA for the 4-17 years age group, has demonstrated the ability to safely desensitize peanut allergic children and adults in a Phase II trial. Aimmune is currently conducting a Phase III trial with AR101 and data are expected in late 2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research